Results 141 to 150 of about 1,056 (174)
A critical evaluation of nemolizumab for prurigo nodularis
Expert Review of Clinical ImmunologyPrurigo nodularis (PN) is a chronic inflammatory skin condition that presents with intensely pruritic, hyperkeratotic nodules. The pathophysiology underlying PN is not entirely clear, making treatment challenging. Patients often require a multimodal approach, although many of the available therapies have low efficacy or adverse effects.In this review ...
exaly +4 more sources
Nemolizumab for atopic dermatitis
Drugs of Today, 2022 Atopic dermatitis (AD) is a common inflammatory skin disease that has emerging treatments targeting the underlying immunological mechanism. Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus.
Angelina, Labib +2 more
openaire +3 more sources
Drugs, 2022 Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic
Susan Keam (4873372)
openaire +3 more sources
Resolution of Lichen Simplex Chronicus With Nemolizumab: A Case Report
Journal of Drugs in DermatologyLichen simplex chronicus is a debilitating condition characterized by lichenified skin secondary to intractable itch. Lichen simplex chronicus is challenging to treat, with current treatment options, such as topical calcineurin inhibitors, gabapentinoids, and dupilumab, commonly being ineffective, leaving patients with worsening symptoms and poor ...
Fiona S, Gruzmark +2 more
openaire +3 more sources
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies* [PDF]
British Journal of Dermatology, 2022 BACKGROUND: Interleukin (IL)‐31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus.
Kenji Kabashima
exaly +2 more sources
Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study [PDF]
Journal of Allergy and Clinical Immunology, 2018 Background: Nemolizumab, an anti–IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind ...
Kenji Kabashima +2 more
exaly +2 more sources
Journal of DermatologyNemolizumab, an anti\u2010interleukin\u201031 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)\u2010associated pruritus.
Ken Igawa, Daisuke Watanabe
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis
Journal of Drugs in Dermatology, 2023Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). Clinical trial results were combined with population PK (popPK) and pharmacokinetic/ pharmacodynamic (PK/PD) models to optimize nemolizumab dosing.
Nathalie, Wagner +11 more
openaire +2 more sources
Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumab
Clinical and Experimental Dermatology, 2023We present a case of perforating dermatosis in a patient with uraemic pruritus who was on haemodialysis and who was successfully treated with nemolizumab, a humanized monoclonal antibody targeted against interleukin-31 receptor A. Nemolizumab may be a treatment option for perforating dermatosis with a uraemic pruritus background. To our knowledge, this
Shun, Ohmori, Yu, Sawada
openaire +2 more sources
Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study [PDF]
Journal of Dermatology, 2019 Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a ...
Masutaka Furue, Ryosuke Mihara
exaly +2 more sources